Ayushmita De
Research Subjects
Ayushmita De has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Adam A. Sassoon
University of California Los Angeles
1 shared publication Adam Rogers
Spinal Simplicity, LLC, Overland Park, KS, USA
1 shared publicationAdam Sassoon
Department of Orthopaedic Surgery, University of California Los Angeles, Los Angeles, CA
1 shared publication- Alexander Upfill-Brown
Department of Orthopedics, Hospital for Special Surgery, New York, NY
1 shared publication Andrew Trobridge
Comprehensive Pain & Spine Specialists, Indianapolis, IN, USA
1 shared publicationAnkur Khosla
AK Pain & Spine Center, Houston, TX, USA
1 shared publication
Latest Publications
- Open Access
- 1 November 2026
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 19, 1-15
Treatment of Lumbar Spinal Stenosis with an Interspinous Fixation and Fusion Device: A Preliminary Multicenter Registry Analysis
Purpose: To evaluate real-world safety and efficacy of a minimally invasive lateral interspinous fixation/fusion device for the treatment of lumbar spinal stenosis. Methods: 105 patients (mean age 70.6 ± 10 years) from ten private pain/spine care centers were entered into the registry for treatment with the device. Analysis was conducted on up to 63 with diagnostic and surgical data, 41 with baseline characteristics, 41 with patient satisfaction data, and 20– 23 with change-based clinical outcome data meeting completeness thresholds. Outcome measures included Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) back and leg pain, and Zurich Claudication Questionnaire (ZCQ) physical function (PF), symptom severity (SS), and satisfaction scores at 6 weeks, 3, 6, 12, and 24 months. A linear mixed effects model was used to evaluate cohort changes from baseline (α=0.05). Results: Most patients had baseline opioid usage (60%), previous injections (77%), moderate to severe stenosis (83%), and markers of segmental instability including fluid in the facet joints and/or spondylolisthesis (73%). Mean blood loss was 9.3 ± 4.7 mL. All outcome measures saw mean improvements at each follow-up, with significant improvement observed as early as 6 weeks for ODI (− 20%, p< 0.05), VAS-back (− 48%, p< 0.001), VAS-leg (− 35%, p< 0.05) and ZCQ-SS (− 26%, p< 0.001). Positive trends continued through 12 months, after which the high loss to follow-up limited interpretation. Patient satisfaction was favorable (80– 100% satisfied at all time points; 91% weighted overall subdomain satisfaction). No complications, adverse events, device failures or migrations, or related follow-on procedures within available early follow-up were reported. Conclusion: Patients commercially treated with a lateral interspinous fixation/fusion device had a high prevalence of prior injections, baseline opioid use, and indicators of segmental instability prior to treatment. Longitudinal analyses were limited by the small sample size but suggest favorable short-term patient-reported outcome trends, with no early adverse safety findings identified.
- 1 November 2026
- Published by Taylor & Francis in Medical Devices: Evidence and Research
- Vol. ume 19, 1-15
Open AccessTreatment of Lumbar Spinal Stenosis with an Interspinous Fixation and Fusion Device: A Preliminary Multicenter Registry Analysis
Purpose: To evaluate real-world safety and efficacy of a minimally invasive lateral interspinous fixation/fusion device for the treatment of lumbar spinal stenosis. Methods: 105 patients (mean age 70.6 ± 10 years) from ten private pain/spine care centers were entered into the registry for treatment with the device. Analysis was conducted on up to 63 with diagnostic and surgical data, 41 with baseline characteristics, 41 with patient satisfaction data, and 20– 23 with change-based clinical outcome data meeting completeness thresholds. Outcome measures included Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) back and leg pain, and Zurich Claudication Questionnaire (ZCQ) physical function (PF), symptom severity (SS), and satisfaction scores at 6 weeks, 3, 6, 12, and 24 months. A linear mixed effects model was used to evaluate cohort changes from baseline (α=0.05). Results: Most patients had baseline opioid usage (60%), previous injections (77%), moderate to severe stenosis (83%), and markers of segmental instability including fluid in the facet joints and/or spondylolisthesis (73%). Mean blood loss was 9.3 ± 4.7 mL. All outcome measures saw mean improvements at each follow-up, with significant improvement observed as early as 6 weeks for ODI (− 20%, p< 0.05), VAS-back (− 48%, p< 0.001), VAS-leg (− 35%, p< 0.05) and ZCQ-SS (− 26%, p< 0.001). Positive trends continued through 12 months, after which the high loss to follow-up limited interpretation. Patient satisfaction was favorable (80– 100% satisfied at all time points; 91% weighted overall subdomain satisfaction). No complications, adverse events, device failures or migrations, or related follow-on procedures within available early follow-up were reported. Conclusion: Patients commercially treated with a lateral interspinous fixation/fusion device had a high prevalence of prior injections, baseline opioid use, and indicators of segmental instability prior to treatment. Longitudinal analyses were limited by the small sample size but suggest favorable short-term patient-reported outcome trends, with no early adverse safety findings identified.
- 15 March 2024
- Published by Elsevier in Seminars in Arthroplasty: JSES
- Vol. 34 (2) , 475-481
Incidence of anatomic total shoulder arthroplasty vs. reverse total shoulder arthroplasty in cuff intact osteoarthritis in males vs. females 70 years or older
- 15 March 2024
- Published by Elsevier in Seminars in Arthroplasty: JSES
- Vol. 34 (2) , 475-481
Incidence of anatomic total shoulder arthroplasty vs. reverse total shoulder arthroplasty in cuff intact osteoarthritis in males vs. females 70 years or older
- Open Access
- 17 March 2022
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 37 (8) , S919-S924.e2
Lower Rates of Ceramic Femoral Head Use in Non-White Patients in the United States, a National Registry Study
- 17 March 2022
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 37 (8) , S919-S924.e2
Open AccessLower Rates of Ceramic Femoral Head Use in Non-White Patients in the United States, a National Registry Study
- 19 February 2022
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 37 (8) , 1570-1574.e1
Modular Metal-Backed Tibial Components Provide Minimal Mid-Term Survivorship Benefits Despite Increased Cost and Frequency of Use: A Retrospective Review of the American Joint Replacement Registry Database
- 19 February 2022
- Published by Elsevier in The Journal of Arthroplasty
- Vol. 37 (8) , 1570-1574.e1
Modular Metal-Backed Tibial Components Provide Minimal Mid-Term Survivorship Benefits Despite Increased Cost and Frequency of Use: A Retrospective Review of the American Joint Replacement Registry Database